We acknowledge the significant work of field teams in sample and data collection and thank all the participants in the study.
World Health Organization , 2020. WHO alliance for the global elimination of trachoma by 2020: progress report, 2019. Wkly Epidemiol Rec 95: 349–360.
Martin DL et al., 2020. The use of serology for trachoma surveillance: current status and priorities for future investigation. PLoS Negl Trop Dis 14: e0008316.
Martin DL et al., 2015. Serology for trachoma surveillance after cessation of mass drug administration. PLoS Negl Trop Dis 9: e0003555.
Senyonjo LG et al., 2018. Serological and PCR-based markers of ocular Chlamydia trachomatis transmission in northern Ghana after elimination of trachoma as a public health problem. PLoS Negl Trop Dis 12: e0007027.
West SK, Zambrano AI, Sharma S, Mishra SK, Munoz BE, Dize L, Crowley K, Gaydos CA, Rotondo LA, 2017. Surveillance surveys for reemergent trachoma in formerly endemic districts in Nepal from 2 to 10 years after mass drug administration cessation. JAMA Ophthalmol 135: 1141–1146.
Goodhew EB, Priest JW, Moss DM, Zhong G, Munoz B, Mkocha H, Martin DL, West SK, Gaydos C, Lammie PJ, 2012. CT694 and Pgp3 as serological tools for monitoring trachoma programs. PLoS Negl Trop Dis 6: e1873.
Gwyn S, Cooley G, Goodhew B, Kohlhoff S, Banniettis N, Wiegand R, Martin DL, 2017. Comparison of platforms for testing antibody responses against the Chlamydia trachomatis antigen Pgp3. Am J Trop Med Hyg 97: 1662–1668.
Gwyn S, Mitchell A, Dean D, Mkocha H, Handali S, Martin DL, 2016. Lateral flow-based antibody testing for Chlamydia trachomatis. J Immunol Methods 435: 27–31.
Horner PJ, Wills GS, Righarts A, Vieira S, Kounali D, Samuel D, Winston A, Muir D, Dickson NP, McClure MO, 2016. Chlamydia trachomatis Pgp3 antibody persists and correlates with self-reported infection and behavioural risks in a blinded cohort study. PLoS One 11: e0151497.
Sun MJ, Zambrano AI, Dize L, Munoz B, Gwyn S, Mishra S, Martin DL, Sharma S, West SK, 2017. Evaluation of a field test for antibodies against Chlamydia trachomatis during trachoma surveillance in Nepal. Diagn Microbiol Infect Dis 88: 3–6.
Gwyn S, Mkocha H, Randall JM, Kasubi M, Martin DL, 2019. Optimization of a rapid test for antibodies to the Chlamydia trachomatis antigen Pgp3. Diagn Microbiol Infect Dis 93: 293–298.
Gwyn S et al., 2021. Comparison of platforms for testing antibodies to Chlamydia trachomatis antigens in the Democratic Republic of the Congo and Togo. Sci Rep 11: 7225.
Nash SD et al., 2021. Population-based prevalence of Chlamydia trachomatis infection and antibodies in four districts with varying levels of trachoma endemicity in Amhara, Ethiopia. Am J Trop Med Hyg 104: 207–215.
Arnold BF, Scobie HM, Priest JW, Lammie PJ, 2018. Integrated serologic surveillance of population immunity and disease transmission. Emerg Infect Dis 24: 1188–1194.
Wiegand RE, Cooley G, Goodhew B, Banniettis N, Kohlhoff S, Gwyn S, Martin DL, 2018. Latent class modeling to compare testing platforms for detection of antibodies against the Chlamydia trachomatis antigen Pgp3. Sci Rep 8: 4232.
Arnold BF, van der Laan MJ, Hubbard AE, Steel C, Kubofcik J, Hamlin KL, Moss DM, Nutman TB, Priest JW, Lammie PJ, 2017. Measuring changes in transmission of neglected tropical diseases, malaria, and enteric pathogens from quantitative antibody levels. PLoS Negl Trop Dis 11: e0005616.
Corran P, Coleman P, Riley E, Drakeley C, 2007. Serology: a robust indicator of malaria transmission intensity? Trends Parasitol 23: 575–582.
Drakeley CJ et al., 2005. Estimating medium- and long-term trends in malaria transmission by using serological markers of malaria exposure. Proc Natl Acad Sci USA 102: 5108–5113.
Gambhir M et al., 2009. The development of an age-structured model for trachoma transmission dynamics, pathogenesis and control. PLoS Negl Trop Dis 3: e462.